<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05090345</url>
  </required_header>
  <id_info>
    <org_study_id>PA19-0756</org_study_id>
    <nct_id>NCT05090345</nct_id>
  </id_info>
  <brief_title>A Prospective Registry of Pediatric Cellular Therapy Patients at Risk for Endothelial Dysfunction, Sinusoidal Obstruction Syndrome and/or Multi-Organ Dysfunction Syndrome (MODS).</brief_title>
  <official_title>A Prospective Registry of Pediatric Cellular Therapy Patients at Risk for Endothelial Dysfunction, Sinusoidal Obstruction Syndrome and/or Multi-Organ Dysfunction Syndrome (MODS).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective international multi-center registry and biorepository trial of children&#xD;
      and adolescents/young adults (AYA) undergoing hematopoietic cell transplantation (HCT) to&#xD;
      assess the impact of endotheliopathies in the HCT setting as a contributor of significant&#xD;
      morbidity and mortality.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary:&#xD;
&#xD;
        -  To evaluate the proportion of pediatric patients undergoing hematopoietic cell&#xD;
           transplant (HCT) who develop endotheliopathies (SOS, TMA, DAH and IPS) and/or MODS&#xD;
           within 100 days of such therapies.&#xD;
&#xD;
        -  To evaluate the proportion of pediatric patients undergoing hematopoietic cell&#xD;
           transplant (HCT) who experience abnormal levels of circulating angiogenic, vascular&#xD;
           permeability and inflammatory factors within 100 days post HCT-CT in the setting of&#xD;
           endotheliopathies.&#xD;
&#xD;
      Secondary/Exploratory Objective(s):&#xD;
&#xD;
        -  To determine the impact of endotheliopathies in the HCT setting on the overall survival.&#xD;
&#xD;
        -  To assess the efficacy of specific prophylaxis and treatment strategies directed at&#xD;
           endotheliopathies (SOS, TMA, DAH and IPS) post-HCT among enrolled children on overall&#xD;
           survival.&#xD;
&#xD;
        -  To assess whether exposure to immunotherapies (CAR-T, PD-1 Inhibitors, bispecific T-cell&#xD;
           engager (BiTE) antibodies and antibody drug conjugates) prior to HCT affects post-HCT&#xD;
           outcomes (endotheliopathies and MODS).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 5, 2021</start_date>
  <completion_date type="Anticipated">February 5, 2026</completion_date>
  <primary_completion_date type="Anticipated">February 5, 2026</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To establish the proportion of pediatric patients undergoing hematopoietic cell transplant (HCT) who develop endotheliopathies (SOS, TMA, DAH and IPS) and/or MODS within 100 days of such therapies.</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Hematopoietic Cell Transplantation</condition>
  <arm_group>
    <arm_group_label>Biorepository trial of children and adolescents/young adults (AYA)</arm_group_label>
    <description>undergoing hematopoietic cell transplantation (HCT) to assess the impact of endotheliopathies in the HCT setting as a contributor of significant morbidity and mortality.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Biorepository Trial</intervention_name>
    <description>participating in this arm, peripheral blood specimen(s) will be obtained at 8 specified time-points.</description>
    <arm_group_label>Biorepository trial of children and adolescents/young adults (AYA)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Children, adolescents and young adults (AYA) 0-26 years of age undergoing HSCT.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Children, adolescents and young adults (AYA) 0-26 years of age undergoing HSCT.&#xD;
&#xD;
          -  Recipients of autologous and allogeneic HSCT.&#xD;
&#xD;
          -  Any preparative regimen.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any patient who does not consent/assent to participation.&#xD;
&#xD;
          -  Any patient for whom 5 mL blood sample(s) drawn at specified intervals would pose any&#xD;
             more than minimal risk, as defined by institutional guidelines and at discretion of&#xD;
             treating physician will be ineligible for biorepository banking.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>26 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kris Mahadeo</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kris Mahadeo</last_name>
    <phone>(713) 792-2873</phone>
    <email>kmmahadeo@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kris Mahadeo</last_name>
      <phone>713-792-2873</phone>
      <email>kmmahadeo@mdanderson.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>M D Anderson Cancer Center website</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 12, 2021</study_first_submitted>
  <study_first_submitted_qc>October 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2021</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatic Veno-Occlusive Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

